Coave Therapeutics is a clinical-stage biotech company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Coave’s next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.